Announcements Trials
Browse Landscape

Phase

Phase 1 2

Status

Terminated 2

Sponsor Class

OTHER 2

Study Type

Interventional 2

Sponsor

Cancer Type

Other hematologic neoplasm 2Myeloid 2

Conditions

Leukemia, Myelogenous, Chronic, BCR-ABL Positive 2Myeloproliferative Disorders 1Leukemia, Myeloid 1Leukemia 1

Interventions

Azacitidine 62Cyclophosphamide 49fludarabine phosphate 46fludarabine 46Cytarabine 34Decitabine 32venetoclax 27Tacrolimus 21Specimen Handling 21Whole-Body Irradiation 19Mycophenolic Acid 19Melphalan 19Filgrastim 19Busulfan 19Imatinib Mesylate 18ruxolitinib 17Biopsy 15Dasatinib 14Antilymphocyte Serum 14Granulocyte Colony-Stimulating Factor 13Etoposide 13Clofarabine 13Peripheral Blood Stem Cell Transplantation 12Sirolimus 11Methotrexate 11Ipilimumab 11Injections 11Thiotepa 10Stem Cell Transplantation 10thymoglobulin 9

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
Phase 1 × zileuton × Myeloid × Clear all
NCT02047149 2016-09-30

Evaluating the Safety of Zileuton (Zyflo®) in Combination With Dasatinib (Sprycel®) in Chronic Myelogenous Leukemia

University of Massachusetts, Worcester

Phase 1 Terminated
2 enrolled
MyeloidOther hematologic neoplasm

Leukemia, Myeloid, Leukemia, Myelogenous, Chronic, BCR-ABL Positive

NCT01130688 2015-05-27

Safety of Zileuton (Zyflo) in Combination With Imatinib Mesylate (Gleevec) in CML.

University of Massachusetts, Worcester

Phase 1 Terminated
2 enrolled
MyeloidOther hematologic neoplasm

Leukemia, Myeloproliferative Disorders, Leukemia, Myelogenous, Chronic, BCR-ABL Positive

Data powered by HemOnc (CC BY 4.0) Colophon ⚡